JN Nova Pharma is a Canadian biotechnology company dedicated to developing transformative therapies for patients with life-threatening diseases that currently have limited or no effective treatment options.
Our proprietary therapeutic platform targets fundamental biological pathways involved in severe lung injury, fibrosis, inflammation, and organ damage. This approach enables the development of multiple therapeutic candidates from a single technology platform across several high-value clinical indications.
The company is supported by an experienced leadership team with extensive expertise in biotechnology innovation, clinical development, regulatory strategy, commercialization, and value creation. Collectively, our leadership has contributed to the successful development and commercialization of globally marketed medicines that have improved millions of lives.
TeamJN Nova Pharma collaborates with leading Canadian universities, hospitals, clinicians, artificial intelligence experts, and biomanufacturing organizations to accelerate clinical translation while maximizing economic benefits for Canada.
Our goal is simple: transform Canadian innovation into globally available medicines that improve patient outcomes while creating high-value jobs, investment, exports, and long-term economic growth.
Platform Opportunity
$40B+
Global market opportunity
~$5B
Canadian opportunity
US$4B+
Estimated annual ARDS market
Lead clinical program
The company's lead clinical program targets ARDS, a life-threatening condition for which no approved pharmacological therapy currently exists. JN Nova estimates the global ARDS market opportunity to exceed US$4 billion annually. To the company's knowledge, JN Nova is the only biotechnology company developing an inhalation based novel enzyme replacement therapy designed to address the underlying root cause of ARDS, rather than providing only supportive care.
Canadian biomanufacturing
JN Nova Pharma is committed to establishing and maintaining Canadian biomanufacturing capabilities. The company is currently producing GMP-grade clinical material in Canada and plans to continue Canadian GMP manufacturing throughout clinical development and commercial stage for next several decades.